D. Tan

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

J. Tabernero, T. Yap, D. Olmos, 2012, British Journal of Cancer.

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.

U. Banerji, S. Kaye, H. Arkenau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.

B. Cho, R. Soo, A. Jazieh, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2013, Cancer Chemotherapy and Pharmacology.

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey

S. Kaye, H. Arkenau, D. Olmos, 2011, Journal of oncology.

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

I. Judson, U. Banerji, S. Kaye, 2010, European journal of cancer.